drugset / Trial / NCT06975514

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

NCT06975514

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Timeline

Start
2025-03-25
Primary completion
2025-07-21
Completion
2025-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject FAZAMOREXANT Small molecule 20 mg
Comparator Zolpidem Small molecule 10 mg

Indications